Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Jason Haas sold 6,461 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $255.58, for a total value of $1,651,302.38. Following the completion of the sale, the director directly owned 4,981 shares of the company’s stock, valued at approximately $1,273,043.98. The trade was a 56.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Ligand Pharmaceuticals Stock Performance
LGND traded down $2.29 on Monday, hitting $253.25. The company had a trading volume of 159,039 shares, compared to its average volume of 195,134. The company’s fifty day moving average price is $226.67 and its 200 day moving average price is $207.09. Ligand Pharmaceuticals Incorporated has a 1-year low of $110.00 and a 1-year high of $259.03. The company has a debt-to-equity ratio of 0.45, a current ratio of 21.28 and a quick ratio of 20.95. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of 34.36, a price-to-earnings-growth ratio of 2.71 and a beta of 1.17.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $1.63 earnings per share for the quarter, missing the consensus estimate of $1.84 by ($0.21). Ligand Pharmaceuticals had a return on equity of 16.19% and a net margin of 55.95%.The company had revenue of $51.72 million during the quarter, compared to analyst estimates of $59.10 million. During the same quarter last year, the firm posted $1.33 earnings per share. The firm’s revenue for the quarter was up 14.1% compared to the same quarter last year. Equities analysts predict that Ligand Pharmaceuticals Incorporated will post 4.47 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Analysis on LGND
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC raised its stake in shares of Ligand Pharmaceuticals by 86.3% in the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 69 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Ligand Pharmaceuticals in the fourth quarter valued at $31,000. USA Financial Formulas acquired a new position in shares of Ligand Pharmaceuticals in the fourth quarter valued at $43,000. Smartleaf Asset Management LLC raised its stake in shares of Ligand Pharmaceuticals by 31.6% in the third quarter. Smartleaf Asset Management LLC now owns 271 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 65 shares in the last quarter. Finally, JPL Wealth Management LLC acquired a new position in shares of Ligand Pharmaceuticals in the third quarter valued at $52,000. 91.28% of the stock is currently owned by institutional investors and hedge funds.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.
The company’s product offerings center around several core platforms.
Featured Stories
- Five stocks we like better than Ligand Pharmaceuticals
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
